| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of epitheaflavin is pancreatic lipase, an enzyme responsible for the hydrolysis of dietary triglycerides. By inhibiting pancreatic lipase, the compound reduces fat absorption, suggesting potential applications in obesity prevention and metabolic disorder research. The compound also modulates cellular signaling pathways involved in cancer and inflammation.
|
|---|---|
| ln Vitro |
In vitro, epitheaflavin inhibits pancreatic lipase activity. It exhibits potent antioxidant activity by neutralizing reactive oxygen species. The compound also demonstrates anti-inflammatory properties and may inhibit tumor growth by modulating cellular signaling pathways. Its strong bioactivity makes it valuable for nutraceutical and functional food research.
|
| ln Vivo |
In vivo studies on epitheaflavin are limited. Based on its mechanism as a pancreatic lipase inhibitor, the compound may reduce dietary fat absorption and support cardiovascular health. Its antioxidant and anti-inflammatory properties suggest potential therapeutic applications in metabolic and inflammatory disorders. Further in vivo studies are needed to fully characterize its pharmacological effects.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, epitheaflavin is tested against pancreatic lipase. The enzyme is incubated with varying concentrations of the compound and a substrate (such as p-nitrophenyl palmitate or triolein) in an appropriate buffer. Lipase activity is measured by monitoring the release of p-nitrophenol (absorbance at 405 nm) or free fatty acids. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, epitheaflavin is typically tested on adipocytes or cancer cell lines. Cells are treated with the compound at various concentrations (typically 1-100 μM) for 24-72 hours. Lipid accumulation in adipocytes can be assessed by Oil Red O staining. Cell viability and proliferation are evaluated using MTT or CCK-8 assays. Apoptosis and signaling pathway modulation can be assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for epitheaflavin have not been extensively reported. Based on its mechanism as a pancreatic lipase inhibitor, potential experimental models include high-fat diet-induced obesity in mice. The compound could be administered orally with the diet, and parameters such as body weight, fat mass, serum lipids, and glucose tolerance would be assessed as pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for epitheaflavin are limited. As a polyphenolic compound with a molecular weight of 564.49 g/mol and formula C₂₉H₂₄O₁₂, it is expected to have moderate oral bioavailability. The compound may undergo metabolism in the gastrointestinal tract and liver. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for epitheaflavin are limited. As a naturally occurring polyphenol from black tea, it is generally considered to have low toxicity at dietary intake levels. However, comprehensive toxicological studies at pharmacological doses have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
Epitheaflavin is a research-use only compound and has not been approved for clinical applications. It is also known as Neotheaflavin and新茶黄素 in Chinese. The compound is a theaflavin-class polyphenol pigment from black tea. Its molecular weight is 564.49 and formula is C₂₉H₂₄O₁₂. It is available from various research chemical suppliers.
|
| Molecular Formula |
C29H24O12
|
|---|---|
| Molecular Weight |
564.494
|
| Exact Mass |
564.126
|
| CAS # |
36451-14-6
|
| PubChem CID |
135911695
|
| Appearance |
Pink to red solid
|
| Source |
Originated from plants: Theaceae Camellia sinensis (L.) O. Ktze.
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
41
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC4=C(C(=C(C=C4[C@@H]5[C@H](CC6=C(C=C(C=C6O5)O)O)O)O)O)C(=O)C(=C3)O)O
|
| InChi Key |
IPMYMEWFZKHGAX-WCQFOESSSA-N
|
| InChi Code |
InChI=1S/C29H24O12/c30-11-3-17(32)15-8-21(36)28(40-23(15)5-11)10-1-13-14(7-20(35)27(39)25(13)26(38)19(34)2-10)29-22(37)9-16-18(33)4-12(31)6-24(16)41-29/h1-7,21-22,28-33,35-37,39H,8-9H2,(H,34,38)/t21-,22+,28-,29-/m1/s1
|
| Chemical Name |
3,4,6-trihydroxy-8-[(2R,3R)-3,5,7-trihydroxy-3,4-dihydro-2H-chromen-2-yl]-1-[(2R,3S)-3,5,7-trihydroxy-3,4-dihydro-2H-chromen-2-yl]benzo[7]annulen-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7715 mL | 8.8576 mL | 17.7151 mL | |
| 5 mM | 0.3543 mL | 1.7715 mL | 3.5430 mL | |
| 10 mM | 0.1772 mL | 0.8858 mL | 1.7715 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
